Ocugen welcomes Dr. Marna Whittington to its Board of Directors

– USA, PA –  Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced the appointment of Dr. Marna Whittington (Ph.D.) to its Board of Directors, effective March 21, 2022.

“We’re extremely pleased to welcome Dr. Marna Whittington to the Ocugen board. Her experiences will be exceedingly important to our growth strategy as we progress our modifier gene therapies and vaccine candidate. I also want to thank Manish Potti for his significant contributions to the Board and the Company,” said Chairman, CEO and co-founder, Dr. Shankar Musunuri. 

Mr. Potti will not seek another term of service on the Board of Directors.

About Dr. Marna C. Whittington

Dr. Whittington is a renowned leader within the financial sector and a sought-after expert serving on numerous boards. She was CEO of Allianz Global Investors Capital from 2001 until her retirement in January 2012. Before that, Dr. Whittington was a corporate officer for Morgan Stanley Investment Management and the University of Pennsylvania as well as the Secretary of Finance for the State of Delaware. She currently serves on the boards of the Salk Institute, Tower Hill School, Macy’s Inc., the Philadelphia Contributionship (a company founded by Benjamin Franklin), Phillips 66, and Oaktree Capital Management.

“This team is making discoveries through courageous innovation and positioning itself to make significant contributions to the health of our communities. I appreciate the opportunity to contribute to its continued success,” said Dr. Marna Whittington.

About Ocugen, Inc.

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing gene therapies, biologicals, and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs.

For more information: https://ocugen.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team